Insulin oral - Generex Biotechnology

Drug Profile

Insulin oral - Generex Biotechnology

Alternative Names: Insulin buccal - Generex; Oral Recosulin; Oral-lyn; Oralgen

Latest Information Update: 30 Oct 2015

Price : $50

At a glance

  • Originator Generex Biotechnology Corporation
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • No development reported Glucose intolerance

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 25 Aug 2015 Pharmacodynamics data from a preclinical trial in Type-II diabetes mellitus released by Generex
  • 24 Mar 2015 Insulin oral is approved for Type-1 diabetes in United Arab Emirates and India; it is awaiting approval in Yemen, Kenya, Iran, Iraq, Libya, Sudan, Syria, Armenia and Bangladesh, and is in phase-III development in Russia, Puerto Rico, Romania, Poland, Bulgaria, Canada, USA and Ukraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top